[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Comment & Response
July 2018

Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2

Author Affiliations
  • 1Women’s College Research Institute, Women’s College Hospital, Toronto, Ontario, Canada
  • 2International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
JAMA Oncol. 2018;4(7):1012. doi:10.1001/jamaoncol.2018.0595

To the Editor Walsh et al1 present data on 1007 Jewish women with breast cancer who were sequenced for 23 candidate genes. There were 111 carriers of a BRCA1 or BRCA2 mutation identified, 29 carriers of a CHEK2 mutation, 1 carrier of an NBN mutation, and 1 carrier of a BRIP1 mutation. The authors use these data to support their position that use of a 23-gene panel is preferable to testing for BRCA1 and BRCA2 alone. We look at the same data and conclude that testing should be limited to BRCA1 and BRCA2.